IP Library Granted Patent US 8,378,105
Granted Patent B2
US 8,378,105 · App. 12/909,241 · Granted Feb 19, 2013

Crystalline pharmaceutical and methods of preparation and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,378,105
App. No.
12/909,241
Granted
Feb 19, 2013
Kind
B2
Abstract

Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

Claims (28)

1. A method of synthesizing a compound of Formula I:

or a salt thereof comprising the steps:

a) performing base hydrolysis of Formula AA with a base in an aprotic solvent:

wherein R is a carbon containing moiety; and

b) isolating a compound of Formula I, or a salt thereof, with an enantiomeric excess of greater than about 90%.

2. The method of claim 1 , wherein the aprotic solvent is dioxane.

3. The method of claim 1 , wherein the base is sodium hydroxide.

4. The method of claim 1 , wherein R is a substituted or unsubstituted group selected from lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, cyclo(lower)alkenyl, aryl, aralkyl, heterocyclyl, and heteroaryl groups.

5. The method of claim 1 , comprising the steps:

a) performing base hydrolysis of Formula A:

with a base in an aprotic solvent; and

b) isolating a compound of Formula I or a salt thereof.

6. The method of claim 5 , wherein the aprotic solvent is dioxane.

7. The method of claim 5 , wherein the base is sodium hydroxide.

8. A method of synthesizing a compound of Formula I:

or a salt thereof comprising the steps:

a) performing acid hydrolysis of Formula AA with an acid in an aprotic solvent:

wherein R is a carbon containing moiety; and

b) isolating a compound of Formula I, or a salt thereof, with an enantiomeric excess of greater than about 90%.

9. The method of claim 8 , wherein the aprotic solvent is dioxane.

10. The method of claim 8 , wherein the acid is hydrogen chloride.

11. The method of claim 8 , wherein R is a substituted or unsubstituted group selected from lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, cyclo(lower)alkenyl, aryl, aralkyl, heterocyclyl, and heteroaryl groups.

12. The method of claim 8 , comprising the steps:

a) performing acid hydrolysis of Formula A:

with an acid in an aprotic solvent; and

b) isolating a compound of Formula I or a salt thereof.

13. The method of claim 12 , wherein the aprotic solvent is dioxane.

14. The method of claim 12 , wherein the acid is hydrogen chloride.

Assignments (9)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 074050/0573 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 074050/0682 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 074050/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2023
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 065789/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 054134/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2019
From: SARCODE BIOSCIENCE INC.
To: NOVARTIS AG
Reel/Frame 050900/0268 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2013
From: SILICON VALLEY BANK
To: SARCODE BIOSCIENCE INC.
Reel/Frame 030295/0028 →
SECURITY AGREEMENT Recorded Feb 8, 2013
From: SARCODE BIOSCIENCE INC.
To: SILICON VALLEY BANK
Reel/Frame 029778/0888 →
CHANGE OF NAME Recorded Sep 8, 2011
From: SARCODE CORPORATION
To: SARCODE BIOSCIENCE INC.
Reel/Frame 026876/0312 →